5 Crucial Metrics Shaping Ethereum’s Next Move: Whale Activity and Network Growth in Focus 
Clinton and Yellen Stand Against Trump's Budget Ax: 'The CDFI Fund Must Be Preserved at All Costs' 
HBAR, OM, and APE Tokens Gear Up for Rally as Binance Reveals Major Trading Pair Expansion 
Is Bitcoin’s Rally in Danger? Five Critical Signs Suggest Bull Run Could Be Nearing Its Peak 
Cybertruck Joins Trump’s Motorcade at SpaceX Starship Test in Texas 
$250B Bitcoin Reserve? Pompliano’s Vision to Make US the King of Crypto 
Vladimir Putin’s Russia Declares War on Crypto Mining With Siberian Energy Limits and Tax Rules 
Bitcoin Soars Past $98,000, Catapults Satoshi Nakamoto Into World's Top 20 Billionaires 
Ram’s First Electric Pickup Delayed Again: 1500 REV Aims to Redefine EV Trucks in 2025 
I’ve studied organisational failure for decades – the Church of England needs more than a new leader 
Why Bitcoin’s Rally Has Traders Eyeing $135K Amid Trump’s Crypto Policy Push and ETF Boom 
Apple Fights Back Against DOJ Monopoly Allegations Amid Rising Big Tech Antitrust Pressure 
Trump Names Crypto Champion Howard Lutnick as Commerce Secretary, Signaling Digital Shift 
Superlobbyist Nick Muzin on Intense Political Campaign Management 
NEW YORK, Aug. 24, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Lipocine Inc. (“Lipocine” or “the Company”) (NASDAQ:LPCN) between June 30, 2015 and June 28, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of New Jersey. To get more information go to:
http://www.zlk.com/pslra/lipocine-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period, defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Lipocine’s filing of its New Drug Application for LPCN 1021, Lipocine’s lead product candidate, contained deficiencies; and (2) as a result, defendant’s statements about Lipocine’s business and operations were false and misleading and/or lacked a reasonable basis.
On June 29, 2016, Lipocine announced that the U.S. Food and Drug Administration had issued a Complete Response Letter regarding the Company’s New Drug Application for LPCN 1021. According to the Complete Response Letter, the FDA has identified deficiencies related to the dosing algorithm for the label and concluded the application was not ready for approval in its present form.
If you suffered a loss in Lipocine you have until August 30, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
